Infliximab to treat Crohn's disease: an update

Risultato della ricerca: Articlepeer review

15 Citazioni (Scopus)


Abstract: Crohn’s disease (CD) is a chronic inflammatory disease of the gastrointestinal tractcharacterized by recurring flares followed by periods of inactive disease and remission. Theetiology is unknown, although the common opinion is that the disease arises from a disorderedimmune response to the gut contents in genetically predisposed individuals. Infliximab (IFX),a chimeric immunoglobulin G1 monoclonal antibody to tumor necrosis factor, has dramaticallychanged the approach to managing patients with CD and improving their treatment, by achievingtreatment goals, such as mucosal healing, and decreasing the need for hospitalizations andsurgeries. This review provides an update on existing evidence for the use of IFX in CD, takinginto account the safety profile in clinical practice and special situations such as pregnancy.Antitumor necrosis factor therapy has been evaluated as an induction and maintenance therapyin CD in several randomized controlled trials and meta-analyses, showing efficacy in bothclinical settings. Early use of biologics may improve patient outcomes in active CD. However,a widespread use of a “top-down” approach in all CD patients cannot be recommended. Clinicalfactors at diagnosis may predict poor outcome in CD, and should be taken into account whendetermining the initial therapeutic approach.Keywords: Crohn’s disease, infliximab, adult
Lingua originaleEnglish
pagine (da-a)227-238
Numero di pagine12
RivistaClinical and Experimental Gastroenterology
Stato di pubblicazionePublished - 2011

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2715???


Entra nei temi di ricerca di 'Infliximab to treat Crohn's disease: an update'. Insieme formano una fingerprint unica.

Cita questo